Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Status:
RECRUITING
Trial end date:
2026-04-22
Target enrollment:
Participant gender:
Summary
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis